Cited by 665Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchBreast Cancer Treatment Studies

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

Open access

Shipley, William U., Seiferheld, Wendy, Lukka, Himanshu R., Major, Pierre P., Heney, Niall M., Grignon, David J., Sartor, Oliver, Patel, Maltibehn P., Bahary, Jean-Paul, Zietman, Anthony L., Pisansky, Thomas M., Zeitzer, Kenneth L., Lawton, Colleen A.F., Feng, Felix Y., Lovett, Richard D., Balogh, Alexander G., Souhami, Luis, Rosenthal, Seth A., Kerlin, Kevin J., Dignam, James J., Pugh, Stephanie L., Sandler, Howard M.·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1607529PMC PMC5444881

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Salvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level. Whether antiandrogen therapy with radiation therapy will further improve cancer control and prolong overall survival is unknown. METHODS: In a double-blind, placebo-controlled trial conducted from 1998 through 2003, we assigned 760 eligible patients who had undergone prostatectomy with a lymphadenectomy and had disease, as assessed on pathological testing, with a tumor stage of T2 (confined to the prostate but with a positive surgical margin) or T3 (with histologic extension beyond the prostatic capsule), no nodal involvement, and a detectable PSA level of 0.2 to 4.0 ng per milliliter to undergo radiation therapy and receive either antiandrogen therapy (24 months of bicalutamide at a dose of 150 mg daily) or daily placebo tablets during and after radiation therapy. The primary end point was the rate of overall survival. RESULTS: The median follow-up among the surviving patients was 13 years. The actuarial rate of overall survival at 12 years was 76.3% in the bicalutamide group, as compared with 71.3% in the placebo group (hazard ratio for death, 0.77; 95% confidence interval, 0.59 to 0.99; P=0.04). The 12-year incidence of death from prostate cancer, as assessed by means of central review, was 5.8% in the bicalutamide group, as compared with 13.4% in the placebo group (P<0.001). The cumulative incidence of metastatic prostate cancer at 12 years was 14.5% in the bicalutamide group, as compared with 23.0% in the placebo group (P=0.005). The incidence of late adverse events associated with radiation therapy was similar in the two groups. Gynecomastia was recorded in 69.7% of the patients in the bicalutamide group, as compared with 10.9% of those in the placebo group (P<0.001). CONCLUSIONS: The addition of 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long-term overall survival and lower incidences of metastatic prostate cancer and death from prostate cancer than radiation therapy plus placebo. (Funded by the National Cancer Institute and AstraZeneca; RTOG 9601 ClinicalTrials.gov number, NCT00002874 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1607529

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)
Cox, J. D., Stetz, J., & Pajak, T. F. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00060-c · Cited by 4,811
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Wilt, T. J., Brawer, M. K., Jones, K. M., Barry, M. J., Aronson, W. J., Fox, S., Gingrich, J. R., Wei, J. T., Gilhooly, P. E., Grob, B. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113162 · Cited by 1,767
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
Bolla, M., González, D., Warde, P. R., Dubois, J. B., Mirimanoff, R., Storme, G. A., Bernier, J., Kuten, A., Sternberg, C. N., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,547
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson, A. J., Scardino, P. T., Kattan, M. W., Pisansky, T. M., Slawin, K. M., Klein, E. A., Anscher, M. S., Michalski, J. M., Sandler, H. M., Lin, D. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9607 · Cited by 889
Self-citation
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 3

American Joint Commission on Cancer. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.
10.2307/2281868 · DOI · Paper page
Mantel N, 1966, Cancer Chemother Rep, 50, 163

Sorted by citations

Items 201–300 of 665

Moderate hypofractionation for salvage radiotherapy (HYPO-SRT) in patients with biochemical recurrence after prostatectomy: A cohort study with meta-analysis
Viani, G. A., Gouveia, A. G., Leite, E. T. T., & de Moraes, F. Y. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.03.006 · Cited by 15
Antagonizing Glutamine Bioavailability Promotes Radiation Sensitivity in Prostate Cancer
Thiruvalluvan, M., Billet, S., & Bhowmick, N. A. (2022) · Cancers · doi:10.3390/cancers14102491 · Cited by 15
Macroscopic locoregional relapse from prostate cancer: which role for salvage radiotherapy?
Bruni, A., Ingrosso, G., Trippa, F., Staso, M. D., Lanfranchi, B., Rubino, L., Parente, S., Frassinelli, L., Maranzano, E., Santoni, R., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02084-0 · Cited by 14
Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy
Bravi, C. A., Tin, A. L., Vertosick, E., Mazzone, E., Bandini, M., Dell’Oglio, P., Stabile, A., Gandaglia, G., Fossati, N., Sjoberg, D. D., et al. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.09.018 · Cited by 14
PSMA-positive nodal recurrence in prostate cancer
Schmidt-Hegemann, N.-S., Büchner, A., Eze, C., Rogowski, P., Schaefer, C., Ilhan, H., Li, M., Fendler, W. P., Bartenstein, P., Ganswindt, U., et al. (2020) · Strahlentherapie und Onkologie · doi:10.1007/s00066-020-01605-z · Cited by 15
Combination Treatment Options for Castration-Resistant Prostate Cancer
Miller, D. R., Ingersoll, M. A., Teply, B. A., & Lin, M. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.prostatecancer.combinationtreatment.2021 · Cited by 14
Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review
Rayhan, M. A., Hossen, M. S., Niloy, M. S., Bhuiyan, M. H., Paul, S., & Shakil, M. S. (2021) · Symmetry · doi:10.3390/sym13060974 · Cited by 14
“Normally, for cancers with low and intermediate-risk, RT is used as an alternative therapeutic tool to control locally advanced cancer instead of surgery [97] or PCa patients who received radical prostatectomy [98].”
Background
PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions
Guévelou, J. L., Achard, V., Mainta, I., Zaidi, H., Garibotto, V., Latorzeff, I., Sargos, P., Ménard, C. M., & Zilli, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.742093 · Cited by 14
Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study
Kaplan, I. D., Bubley, G. J., Bhatt, R. S., Taplin, M., Dowling, S., Mahoney, K. M., Werner, E., & Nguyen, P. L. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.02.027 · Cited by 14
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer
Kishan, A. U., Tendulkar, R. D., Tran, P. T., Parker, C. C., Nguyen, P. L., Stephenson, A. J., & Carrié, C. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.02.008 · Cited by 14
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials
Shelan, M., Achard, V., Appiagyei, F., Mose, L., Zilli, T., Fankhauser, C. D., Zamboglou, C., Mohamad, O., Aebersold, D. M., & Cathomas, R. L. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00829-9 · Cited by 13
Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP
Supiot, S., Campion, L., Pommier, P., Dore, M., Palpacuer, C., Racadot, S., Rio, E., Milano, G. A., Oukhatar, C. M. A., & Carrié, C. (2018) · Oncotarget · doi:10.18632/oncotarget.25189 · Cited by 13
Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer
Zaorsky, N. G., Sun, Y., Nabid, A., Zapatero, A., Bolla, M., Joseph, D. J., Maingon, P., Guerrero, A., Gonzalez, A. A., Segundo, C. G. S., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.4800 · Cited by 12
Self-citation
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis
Kishan, A. U., Sun, Y., Parker, C. C., Sargos, P., Sydes, M. R., Chabaud, S., Brihoum, M., Romero, T., Steinberg, M. L., Valle, L., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00137-6 · Cited by 12
“7 The lack of an overall survival benefit to adding hormone therapy to PORT was supported by the results of a recent aggregate study-level meta-analysis of these trials.”
Self-citation
Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer
Efstathiou, J. A., Morgans, A. K., Bland, C. S., & Shore, N. D. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102630 · Cited by 12
18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE
Solanki, A. A., Savir-Baruch, B., Liauw, S. L., Michalski, J. M., Tward, J. D., Vapiwala, N., Teoh, E., Adler, L. P., Andriole, G. L., Belkoff, L. H., et al. (2020) · Practical Radiation Oncology · doi:10.1016/j.prro.2020.05.007 · Cited by 12
The effects of PSA kinetics on the outcome of hypofractionated salvage radiotherapy for biochemical recurrence of prostate cancer after prostatectomy
Ishikawa, H., Higuchi, K., Kaminuma, T., Takezawa, Y., Saito, Y., Etsunaga, T., Maruo, K., Kawamura, H., Kubo, N., Nakano, T., et al. (2020) · Journal of Radiation Research · doi:10.1093/jrr/rraa074 · Cited by 12
“A randomized control trial (RTOG 9601) showed that a combination of 24-month antiandrogen therapy with S-RT improved not only bRFS but also OS in PC patients with BR after RP [30].”
Salvage-Radiation Therapy and Regional Hyperthermia for Biochemically Recurrent Prostate Cancer after Radical Prostatectomy (Results of the Planned Interim Analysis)
Beck, M., Ghadjar, P., Mehrhof, F. B., Zips, D., Paulsen, F., Wegener, D., Burock, S., Kaul, D., Stromberger, C., Nadobny, J., et al. (2021) · Cancers · doi:10.3390/cancers13051133 · Cited by 12
“In the first trial, an advantage in overall survival (OS), cancer-specific survival (CSS), and metastasis-free survival (MFS), particularly for patients with high-risk factors, were observed, and in the second trial, an improvement in freedom of biochemical and clinical progression [17,18].”
Background
Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Versus Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer
Vogel, M. M. E., Dewes, S., Sage, E. K., Devečka, M., Eitz, K. A., Gschwend, J. E., Eiber, M. J., Combs, S. E., & Schiller, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.715020 · Cited by 12
Genomic biomarkers to guide precision radiotherapy in prostate cancer
Sutera, P. A., Deek, M. P., der Eecken, K. V., Wyatt, A. W., Kishan, A. U., Molitoris, J. K., Ferris, M. J., Siddiqui, M. M., Rana, Z. H., Mishra, M. V., et al. (2022) · The Prostate · doi:10.1002/pros.24373 · Cited by 12
Self-citation
The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis‐free survival in patients with relapsed prostate cancer following prostatectomy
Lee, E. E., Singh, T., Hu, C., Han, M., Deville, C., Halthore, A. N., Greco, S. C., Tran, P. T., DeWeese, T. L., & Song, D. Y. (2022) · The Prostate · doi:10.1002/pros.24452 · Cited by 12
SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
Rans, K., Berghen, C., Ameye, F., Hertogh, O. D., den Hartog, J., Céderic, D., Dumez, H., Benedikt, E., Karolien, G., Laenen, A., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10374-0 · Cited by 12
“Two recent trials also suggested a progression-free by adding temporary ADT to salvage RT, especially among young and fit patients [19, 20].”
Background
hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen‐induced transcriptional response in prostate cancer
Adams, M. N., Croft, L. V., Urquhart, A. J., Saleem, M.-A. M., Rockstroh, A., Duijf, P. H. G., Thomas, P. B., Ferguson, G. P., Najib, I. M., Shah, E. T., et al. (2023) · The Prostate · doi:10.1002/pros.24496 · Cited by 12
Does Prophylactic Radiation Therapy to Avoid Gynecomastia in Patients With Prostate Cancer Increase the Risk of Breast Cancer?
Aksnessæther, B. Y., Solberg, A., Klepp, O., Myklebust, T. Å., Skovlund, E., Hoff, S. R., VATTEN, L. J., & Lund, J. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.01.096 · Cited by 12
Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer–specific Mortality: Competition Between Age and Time to Biochemical Failure
Jackson, W., Suresh, K., Tumati, V., Dess, R. T., Soni, P., Zhao, S. G., Zumsteg, Z. S., Hannan, R., Hollenbeck, B. K., George, A. K., et al. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.04.014 · Cited by 12
Self-citation
Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician’s guide
Young, S., Liu, W., Zukotynski, K., & Bauman, G. S. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1878883 · Cited by 12
Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis
Song, C., Byun, S. J., Kim, Y. S., Ahn, H., Byun, S., Kim, C., Lee, S. E., & Js, K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215057 · Cited by 12
5-Year Outcomes of a Prospective Phase 1/2 Study of Accelerated Hypofractionated Radiation Therapy to the Prostate Bed
Martell, K., Cheung, P., Morton, G., Chung, H. T.-K., Deabreu, A., Zhang, L., Pang, G., Alayed, Y. M., Mamedov, A., Gladwish, A. P., et al. (2019) · Practical Radiation Oncology · doi:10.1016/j.prro.2019.04.010 · Cited by 12
Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?
Hussain, M., Lin, D. W., Fred Saad, C., Vapiwala, N., Chapin, B. F., Sandler, H. M., Evans, C. P., Carducci, M. A., & Sachdev, S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02268 · Cited by 12
Self-citation
Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy
Metz, R., Rauscher, A., Vaugier, L., Supiot, S., Drouet, F., Campion, L., & Rousseau, C. (2023) · Cancers · doi:10.3390/cancers15061898 · Cited by 11
Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer
Ganguly, S., Lone, Z. M., Muskara, A., Imamura, J., Hardaway, A., Patel, M., Berk, M., Smile, T. D., Davicioni, E., Stephans, K. L., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165718 · Cited by 11
Self-citation
Toxicity profile and Patient-Reported outcomes following salvage Stereotactic Ablative Radiation Therapy to the prostate Bed: The POPART multicentric prospective study
Ferrario, F., Franzese, C., Faccenda, V., Vukcaj, S., Belmonte, M., LUCCHINI, R., Baldaccini, D., Badalamenti, M., Andreoli, S., Panizza, D., et al. (2023) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2023.100704 · Cited by 11
“Several phase III randomized clinical trials have demonstrated that post-prostatectomy RT improves overall (OS) and progression-free survival (PFS), either as adjuvant or early salvage treatment [3 – 7].”
Background
Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy
Lukka, H. R., Pugh, S. L., Shipley, W. U., Major, P. P., Sartor, O., Dayes, I. S., Bahary, J.-P., Efstathiou, J. A., Pisansky, T. M., Zeitzer, K. L., et al. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.07.1416 · Cited by 11
Self-citation
Radiotherapy in nodal oligorecurrent prostate cancer
Pinkawa, M., Aebersold, D. M., Böhmer, D., Flentje, M. P., Ghadjar, P., Schmidt-Hegemann, N.-S., Höcht, S., Hölscher, T., Müller, A., Niehoff, P., et al. (2021) · Strahlentherapie und Onkologie · doi:10.1007/s00066-021-01778-1 · Cited by 11
“45) [27, 28] ADT in patients with biochemical recurrence (without PET/CT staging).”
Background
Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner
Eke, I., Aryankalayil, M. J., Bylicky, M. A., Makinde, A. Y., Liotta, L. A., Calvert, V. S., Petricoin, E. F., Graves, E. E., & Coleman, C. N. (2022) · Scientific Reports · doi:10.1038/s41598-022-07394-y · Cited by 11
Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy
Zaine, H., Vandendorpe, B., Bataille, B., Lacornerie, T., Wallet, J., Mirabel, X., Lartigau, E. F., & Pasquier, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.669261 · Cited by 11
“The benefits of additional hormone therapy vary depending on the pathological characteristics and make it possible to prolong metastasis-free survival (5, 6).”
Background
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer
Li, H., Melnyk, J. E., Fu, B. X. H., Shrestha, R., Zhang, M., Sjöström, M., Feng, S., Anderson, J. A., Han, W., Chesner, L. N., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02388-8 · Cited by 10
Self-citation
Hyaluronic acid spacer in focal prostate reirradiation: A single centre experience
Özyiğit, G., Hürmüz, P., Akıncı, D., Esen, C. S. B., Yılmaz, M. T., Akdoğan, B., & Akyol, F. H. (2020) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2020.03.009 · Cited by 10
Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis
Matsukawa, A., Yanagisawa, T., Fazekas, T., Miszczyk, M., Tsuboi, I., Parizi, M. K., Laukhtina, E., Klemm, J., Mancon, S., Mori, K., et al. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00890-4 · Cited by 10
“2.”
Influential
Therapeutic options in patients with biochemical recurrence after radical prostatectomy (Review)
Bratu, O. G., Diaconu, C. C., Mischianu, D. L. D., Constantin, T. V., Stănescu, A. M. A., BUNGAU, S. G., Radu, F. I., & Marcu, R. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7916 · Cited by 10
Salvage low-dose-rate brachytherapy for local recurrences after prostatectomy and adjuvant or salvage external beam irradiation: Feasibility study on five patients and literature review
Roy, C. L., Gassa, F., Rouvière, O., Desmettre, O., Bringeon, G., Charret, J., Serre, A.-A., & Pommier, P. (2020) · Brachytherapy · doi:10.1016/j.brachy.2020.07.001 · Cited by 10
Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?
Zattoni, F., Heidegger, I. M., Kasivisvanathan, V., Kretschmer, A., Marra, G., Magli, A., Preißer, F., Derya Tilki, A., Tsaur, I., Massimo Valerio, A., et al. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.691473 · Cited by 10
“5 ng/ml) and GETUG-AFU 16 showed an advantage in progression free survival and metastasis-free survival, for the use of 6months Goserelin (39, 40).”
MethodInfluential
Three Months’ PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy—STARR (NCT05455736)
Francolini, G., Garlatti, P., Cataldo, V. D., Detti, B., Loi, M., Greto, D., Simontacchi, G., Morelli, I., Burchini, L., Allegra, A. G., et al. (2023) · Cancers · doi:10.3390/cancers15030992 · Cited by 10
“One biochemical relapse at first evaluation has been registered and the patient started ADT; seven patients had stable PSA if compared to baseline and continued observation.”
BackgroundMethodInfluential
Role of Tripodal DNA Modified Gold Nanoparticles in Colorimetric Aptasensing
Kou, X., Liu, T., Yang, X., Tang, Y., Gong, X. N., & Miao, P. (2017) · Colloids and Interface Science Communications · doi:10.1016/j.colcom.2017.11.001 · Cited by 10
Effective Prediction of Prostate Cancer Recurrence through the IQGAP1 Network
Gu, Y. J., Lin, X., Kapoor, A., Li, T., Major, P. P., & Tang, D. (2021) · Cancers · doi:10.3390/cancers13030430 · Cited by 10
“A large percentage of BCR tumors will progress to metastatic PCs [7].”
BackgroundSelf-citation
The impact of reinsurance of gene therapies on employer financial risk
Hixson, M., Minkoff, N. B., Gwiazdzinski, K., & Clement, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88653 · Cited by 10
Expert survey on management of prostate cancer in India
Bakshi, G., Tongaonkar, H. B., Addla, S. K., Menon, S. G., Pradhan, A., Kumar, A., Bapat, A., Gore, A. A., Joshi, A., Raja, A., et al. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_1145_21 · Cited by 10
Drug development for noncastrate prostate cancer in a changed therapeutic landscape
Teo, M. Y., O’Shaughnessy, M. J., McBride, S. M., Vargas, H. A., & Scher, H. I. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.160 · Cited by 10
Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy
Vogel, M. M. E., Kessel, K. A., Schiller, K., Devečka, M., Gschwend, J. E., Weichert, W., Wilkens, J. J., & Combs, S. E. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1391-0 · Cited by 10
Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer
Spratt, D. E. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.06.037 · Cited by 10
“5 ng/mL, consistent with the data from RTOG 9601 in that men with higher PSA had both a greater absolute and relative benefit from hormone therapy (1, 2).”
MethodResult
Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol
Staal, F. H. E., Janssen, J., Brouwer, C. L., Langendijk, J. A., Siang, K. N. W., Schuit, E., de Jong, I. J., Verzijlbergen, J. F., Smeenk, R. J., & Aluwini, S. (2022) · BMC Cancer · doi:10.1186/s12885-022-09493-5 · Cited by 10
“within the PERYTON‐study Two phase III RCTs have shown superior outcomes after postoperative sEBRT when androgen deprivation therapy (ADT) was added (6 months of LHRH-analogues or 24 months of bicalutamide) [26, 27].”
Background
RADICALS-HD: Reflections before the Results are Known
Parker, C. C., Clarke, N. W., Catton, C., Kynaston, H., Cook, A. D., Cross, W. R., Davidson, C., Goldstein, C., Logue, J. P., Maniatis, C., et al. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.06.004 · Cited by 10
[18F]-Fluciclovine or [68Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial
Jani, A. B., Dhere, V. R., Goyal, S., Schreibmann, E., Patel, P. R., Hershatter, B. W., Shelton, J. W., Hanasoge, S., Sebastian, N., Patel, S. A., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.12.003 · Cited by 9
Are all prostate cancer patients "fit" for salvage radiotherapy?
Segundo, C. G. S., Iturriaga, A. G., & Couñago, F. (2019) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i1.1 · Cited by 9
Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?
Patrikidou, A., Zilli, T., Baciarello, G., Terrisse, S. A., Hamilou, Z., & Fizazi, K. S. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211051870 · Cited by 9
Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer
Lee, S. U., Js, K., Kim, Y. S., Cho, J., Choi, S. H., Nam, T., Jeong, S. M., Kim, Y., Choi, Y., Lee, D.-E., et al. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.985 · Cited by 9
“3 ng/mL [9], have been used in previous studies of the efficacy of SRT and adopted as definitions of BCR in measurements of BCR-free survival.”
Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy
Beck, M., Wust, P., Barelkowski, T., Kaul, D., Thieme, A. H., Wecker, S., Wlodarczyk, W., Budach, V., & Ghadjar, P. (2017) · Radiation Oncology · doi:10.1186/s13014-017-0862-4 · Cited by 9
“Notable differences in toxicity between both arms were a rate of 70% gynecomastia in the bicalutamide group versus 11% in the SRT only group [30].”
Background
Prognostic significance of lymphovascular invasion in patients with prostate cancer treated with postoperative radiotherapy
Jeong, J., Nam, T., Song, J., Yoon, M. S., Ahn, S., Chung, W., Cho, I. J., Kim, Y.-H., Cho, S. H., Jung, S. I., et al. (2019) · Radiation Oncology Journal · doi:10.3857/roj.2019.00332 · Cited by 9
“The results of a randomized trial, RTOG 9601, advocated the use of CA-ADT for patients who received postoperative salvage RT [28].”
Background
A narrative review of oligometastatic prostate cancer—an evolving paradigm
Sritharan, K., Rieu, R., & Tree, A. C. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-1215 · Cited by 9
“There is robust evidence that ADT, in combination with primary radiotherapy, or salvage prostate bed radiotherapy, improves survival (111-114).”
Background
The prognostic value, sensitivity, and specificity of multiparametric magnetic resonance imaging before salvage radiotherapy for prostate cancer
Breen, W. G., Stish, B. J., Harmsen, W. S., Froemming, A. T., Mynderse, L. A., Choo, C. R., Davis, B. J., & Pisansky, T. M. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.05.015 · Cited by 9
Self-citation
Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy
Laughlin, B. S., Voss, M. M., Toesca, D. A. S., Daniels, T. B., Golafshar, M. A., Keole, S. R., Wong, W. W., Rwigema, J. M., Davis, B. J., Schild, S. E., et al. (2022) · Advances in Radiation Oncology · doi:10.1016/j.adro.2022.101143 · Cited by 9
The evolving role of molecular profiling in prostate cancer: basal and luminal subtyping transcends tissue of origin
Mian, O. Y., Tendulkar, R. D., & Abazeed, M. E. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.10.49 · Cited by 9
“In the wake of recent randomized trials demonstrating a cumulative benefit to the addition of ADT in the post-operative recurrence setting (21,22), clinicians find themselves in need of tools to better identify exactly which men derive a benefit from concurrent ADT and salvage radiotherapy.”
Background
Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy
Gunnarsson, O., Schelin, S., Brudin, L. H., Carlsson, S., & Damber, J. (2019) · Scandinavian Journal of Urology · doi:10.1080/21681805.2019.1600580 · Cited by 9
“Waiting with ADT until after RP, but initiated before adjuvant RT as described in two studies [14,15], showed a survival benefit on prolongation of the ADT treatment up to 24 months.”
Method
Post-Operative Radiotherapy in Prostate Cancer: Is It Time for a Belt and Braces Approach?
Giraud, N., Benziane-Ouaritini, N., Schick, U., Beauval, J., Chaddad, A., Niazi, T. M., Faye, M. D., Supiot, S., Sargos, P., & Latorzeff, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.781040 · Cited by 9
Studies on aflatoxin synthesis in Aspergillus flavus.
Naik, M., Modi, V. V., & Patel, N. (1970) · PubMed · Cited by 9
Surrogacy validation for time‐to‐event outcomes with illness‐death frailty models
Roberts, E., Elliott, M. R., & Taylor, J. M. G. (2023) · Biometrical Journal · doi:10.1002/bimj.202200324 · Cited by 8
“In this work, our data come from a prostate cancer clinical trial assessing the addition of an antiandrogen therapy to an existing regimen (Shipley et al., 2017).”
Method
Delayed definitive management of localized prostate cancer: what do we know?
Mohamad, O., Li, Y. R., Feng, F. Y.-C., Hong, J. C., Wong, A., Kouzi, Z. E., Shelan, M., Zilli, T., Carroll, P. R., & Roach, M. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00876-2 · Cited by 8
“Of note, data from randomized studies suggests that salvage RT at earlier pre-RT PSA improves outcomes (RTOG 9601, RTOG 0534, and GETUG-AFU 16) [43 – 45] and the role of NHT to delay RT in that setting is less well understood.”
Self-citation
Development and Validation of a Multimodal Artificial Intelligence–derived Digital Pathology–based Biomarker Predicting Metastasis Among Patients with Biochemical Recurrence After Radical Prostatectomy in NRG/RTOG Trials
Morgan, T. M., Ren, Y., Tang, S., Zwerink, W., Chen, E., Mitani, A., Huang, H.-C. R., Simko, J., DeVries, S., Pollack, A. S., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.12.007 · Cited by 8
Self-citation
PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients
Fersino, S., Borghesi, S., Jereczek‐Fossa, B. A., Arcangeli, S., Mortellaro, G., Magrini, S. M., & Alongi, F. (2020) · La radiologia medica · doi:10.1007/s11547-020-01264-1 · Cited by 8
“Two major randomized studies managed by Radiation Therapy Oncology Group (RTOG 9601) [21] and Genitourinary Group—French Association of Urology (GETUGAFU 16) [22] confirmed the importance to combine ADT with SRT in order to improve, respectively, overall survival and progression free survival.”
Background
Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial
Bitting, R. L., Wu, Y. S., Somarelli, J. A., Proudfoot, J. A., Liu, Y., Davicioni, E., George, D. J., & Armstrong, A. J. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00214 · Cited by 8
Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy
Holliday, E. B., Kuban, D. A., Levy, L. B., Bölükbaşı, Y., Master, P., Choi, S., Nguyen, Q., McGuire, S. E., Mahmood, U., Frank, S. J., et al. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2017.24 · Cited by 8
Importance of the site of positive surgical margin in salvage external beam radiation therapy for biochemical recurrence of prostate cancer after radical prostatectomy
Kashihara, T., Nakamura, S., Wakita, A., Okamoto, H., Inaba, K., Umezawa, R., Shima, S., Tsuchida, K., Kobayashi, K., Takahashi, K., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1408 · Cited by 8
Two years of bicalutamide monotherapy in patients with biochemical relapse after radical prostatectomy
Okubo, T., Mitsuzuka, K., Koie, T., Hoshi, S., Matsuo, S., Saito, S., Tsuchiya, N., Habuchi, T., Οhyama, C., Arai, Y., et al. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy060 · Cited by 8
Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival
Casas, F., Valduvieco, I., Oses, G., Izquierdo, L., Archila, I., Costa, M., Cortes, K., Barreto, T., & Ferrer, F. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1931-3 · Cited by 8
Association between PSA values and surveillance quality after prostate cancer surgery
Chapman, C. H., Caram, M. E. V., Radhakrishnan, A., Tsodikov, A. D., Deville, C., Burns, J., Zaslavsky, A., Chang, M., Leppert, J. T., Hofer, T. P., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2663 · Cited by 8
Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer’s Disease and Neurodegeneration: Old Drugs, New Concerns
Achard, V., Ceyzériat, K., Tournier, B. B., Frisoni, G. B., Garibotto, V., & Zilli, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734881 · Cited by 8
A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy – The PROPER 1 trial
Gunnlaugsson, A., Jóhannesson, V., Wieslander, E., Brun, E., Bitzèn, U., Ståhl, O., Ola Bratt, A., Ahlgren, G., Ohlsson, T. G., Kjellén, E., et al. (2022) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2022.07.001 · Cited by 8
“Patients who were undergoing or had undergone previous ADT, or who had a history of previous pelvic radiotherapy or malignancies other than prostate cancer or basal cell carcinoma in the past five years were also excluded.”
Background
Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era
Tamihardja, J., Zehner, L., Hartrampf, P. E., Cirsi, S., Wegener, S., Buck, A. K., Flentje, M. P., & Polat, B. (2022) · Cancers · doi:10.3390/cancers14194956 · Cited by 8
“In the case of SRT for recurrent prostate cancer, the patients may benefit from additional hormonal therapy [24,30].”
Background
The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update
Kauffmann, G., & Liauw, S. L. (2017) · Current Urology Reports · doi:10.1007/s11934-017-0698-3 · Cited by 8
Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy
Jensen, L. G., Yuh, B. E., Wong, J. Y. C., Schultheiss, T. E., Cheng, J., Ruel, N. H., Twardowski, P. W., & Sampath, S. (2017) · Advances in Radiation Oncology · doi:10.1016/j.adro.2017.08.004 · Cited by 8
Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes
Segundo, C. G. S., Jové, J., Zapatero, A., Peidro, J. P., Vázquez, M., Casaña, M., Mengual, J. L., Gómez‐Caamaño, A., Iturriaga, A. G., Vallejo, C., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02021-7 · Cited by 8
Impact of timing on salvage radiation therapy adverse events following radical prostatectomy: A secondary analysis of the RTOG 9601 cohort
Baumgarten, L., Borchert, A., Sood, A., Dalela, D., Arora, S., Keeley, J., ROGERS, C. G., Peabody, J. O., Menon, M., & Abdollah, F. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.09.012 · Cited by 8
Surrogate Endpoints in Localized Prostate Cancer
Hartman, H. E., & Jackson, W. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000422 · Cited by 8
Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients
Lyou, Y., & Dorff, T. B. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1053 · Cited by 8
“Recently large randomized trials indicate an advantage to the addition of ADT during salvage radiation (22,23).”
Stereotactic body radiotherapy (SBRT) re-irradiation for local failures following radical prostatectomy and post-operative radiotherapy
Majewski, W., Miszczyk, M., Gräupner, D., Goc, B., Goldner, G. M., & Napieralska, A. (2023) · Strahlentherapie und Onkologie · doi:10.1007/s00066-023-02187-2 · Cited by 7
A randomised trial of short‐ vs long‐term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06‐24
Segundo, C. G. S., López‐Campos, F., Iturriaga, A. G., Pérez, A. R., Olivera, J., Duque‐Santana, V., Sancho, G., Henriquez, I., Conde-Moreno, A. J., Valero, J., et al. (2024) · British Journal of Urology · doi:10.1111/bju.16484 · Cited by 7
Undetectable PSA predicts outcome after salvage radiotherapy for biochemical recurrence following radical prostatectomy
Scharl, S., Gartner, L., Böhmer, D. H. G., Siegmann, A. D., Thamm, R., Krafcsik, M., Mayer, B., Zips, D., Ruf, C. G., & Wiegel, T. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110476 · Cited by 7
Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Bryce, A. H., Agarwal, N., Beltran, H., Hussain, M., Sartor, O. A., Shore, N. D., Antonarakis, E. S., Armstrong, A. J., Calais, J., Carducci, M. A., et al. (2024) · Cancer · doi:10.1002/cncr.35612 · Cited by 7
Self-citation
Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study
Kucharczyk, M. J., Tsui, J. M. G., Khosrow‐Khavar, F., Bahoric, B., Souhami, L., Anidjar, M., Probst, S., Chaddad, A., Sargos, P., & Niazi, T. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00312 · Cited by 7
“McGill 0913 investigated the efficacy and toxicity of PBRT treatment escalation with PNRT and LTADT in patients with a pathological high risk of recurrence following prostatectomy.”
BackgroundResultInfluentialSelf-citation
Management of early-stage metastatic prostate cancer: appraisal of locoregional treatments and radiation therapy, with or without immunomodulation
Sandoval, M. L., Dohm, A. E., & Yamoah, K. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0073 · Cited by 7
Effect of Salvage Radiotherapy and Endocrine Therapy on Patients with Biochemical Recurrence After Prostate Cancer Operation— a Meta‑Analysis
Yuan, Y., Zhang, Q., Xie, C., & Wu, T. (2021) · American Journal of Men s Health · doi:10.1177/15579883211024881 · Cited by 7
“The results showed that the combination of drugs can slightly improve survival time (HR: 0.76; 95% CI, 0.59–0.99; p = .04) (Struss & Black, 2017).”
BackgroundInfluential
Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial
Tree, A. C., Griffin, C. L., Syndikus, I., Birtle, A. J., Choudhury, A., Graham, J., Ferguson, C., Khoo, V. S., Malik, Z., O’Sullivan, J. M., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.12.160 · Cited by 7
“In the salvage radiation therapy setting, bicalutamide has been shown to reduce overall mortality.(8) To the best of our knowledge, there are no large randomized studies which have compared bicalutamide with LHRHa combined with radiation therapy.”
Background
Impact of Dose Escalation on the Efficacy of Salvage Radiotherapy for Recurrent Prostate Cancer—A Risk-Adjusted, Matched-Pair Analysis
Böhmer, D., Siegmann, A. D., Scharl, S., Ruf, C. G., Wiegel, T., Krafcsik, M., & Thamm, R. (2022) · Cancers · doi:10.3390/cancers14051320 · Cited by 7
“Two randomized trials evaluated the addition of androgen deprivation therapy (ADT) to SRT, but the results were inconclusive [10,11].”
Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data
Sood, A., Keeley, J., Palma‐Zamora, I., Chien, M., Corsi, N. J., Jeong, W., ROGERS, C. G., Trinh, Q., Peabody, J. O., Menon, M., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11892-8 · Cited by 7
“A detailed description of the RTOG-9601 trial cohort (n = 760) has been previously published.(7) Briefly, the trial recruited patients at high risk for biochemical failure, i.”
Method
How can we best manage biochemical failure after radical prostatectomy?
Kim, W. T., Kim, J., & Kim, W. (2022) · Korean journal of urology · doi:10.4111/icu.20220294 · Cited by 7
“[70] conducted a double-blind, placebo-controlled trial from 1998 to 2003.”
Method
Treatment outcomes of postoperative ultra-hypofractionated stereotactic body radiotherapy in prostate cancer
Özyiğit, G., Önal, C., Esen, C. S. B., Tilki, B., & Hürmüz, P. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.12.001 · Cited by 7
Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review
Parimi, S., & Ko, J. J. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1359544 · Cited by 7
Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer
Wu, J., Chen, W., Zhang, W., Zhang, J., Liu, J., Jiang, Y., & Fang, K.-W. (2017) · Oncotarget · doi:10.18632/oncotarget.19810 · Cited by 7
“Salvage radiotherapy is often necessary in men who have undergone radical prostatectomy but show evidence of PC recurrence signaled by persistently or recurrently elevated prostate-specific antigen (PSA) levels [15].”
Background
Chemotherapy for oligometastatic prostate cancer
Dorff, T. B., & Sweeney, C. J. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000446 · Cited by 7
Approach to the Patient with High-Risk Prostate Cancer
Mossanen, M., Krasnow, R. E., Nguyen, P. L., Trinh, Q. D., Preston, M. A., & Kibel, A. S. (2017) · Urologic Clinics of North America · doi:10.1016/j.ucl.2017.07.009 · Cited by 7

Authors: Shipley, W. U., Seiferheld, W., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., Sartor, O., Patel, M. P., Bahary, J.-P., Zietman, A. L., Pisansky, T. M., Zeitzer, K. L., Lawton, C. A. F., Feng, F. Y., Lovett, R. D., Balogh, A. G., Souhami, L., Rosenthal, S. A., Kerlin, K. J., Dignam, J. J., Pugh, S. L., & Sandler, H. M.
Affiliations: Cedars-Sinai Medical Center (US)
Tulane University (US)
ORCID: Shipley, William U.
Major, Pierre P.
Grignon, David J.
Sartor, Oliver
Bahary, Jean-Paul
Zietman, Anthony L.
Pisansky, Thomas M.
Zeitzer, Kenneth L.
Feng, Felix Y.
Rosenthal, Seth A.
Dignam, James J.
Pugh, Stephanie L.
Sandler, Howard M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2017-02-02
Volume: 376
Issue: 5
Pages: 417-428
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1607529
PMC: PMC5444881
OpenAlex: W2585109238
Cited by: 663
References: 29
Citations by year: 2026: 32 · 2025: 54 · 2024: 65 · 2023: 50 · 2022: 63 · 2021: 84 · 2020: 81 · 2019: 86 · 2018: 78 · 2017: 68
FWCI: 70.79
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (UG1CA189867, U10CA180868, U10CA180801, U10CA021661, U10CA180822)
Topics: Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: recurrent prostate cancer, salvage radiotherapy, antiandrogen therapy, bicalutamide, prostate-specific antigen, radical prostatectomy, overall survival, metastatic prostate cancer, gynecomastia, androgen deprivation therapy, lymph node dissection, long-term follow-up
MeSH terms: Aged, Aged, 80 and over, Androgen Antagonists, Anilides, Combined Modality Therapy, Double-Blind Method, Follow-Up Studies, Gynecomastia, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Staging, Nitriles, Prostatectomy, Prostatic Neoplasms, Radiotherapy, Tosyl Compounds, Incidence, Survival Rate, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks